A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial
暂无分享,去创建一个
P. Validire | F. Bonnetain | P. Hammel | J. Bachet | T. André | C. Louvet | B. Chibaudel
[1] B. Dörken,et al. SPARC expression in resected pancreatic cancer patients treated with Gemcitabine: results from the CONKO-001 study. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] P. Laurent-Puig,et al. Tu1942 hENT1 Testing in Pancreatic Ductal Adenocarcinoma: Are We Ready yet? A Comparative Analysis of the Murine and the Rabbit Antibodies , 2015 .
[3] J. Cros,et al. Human equilibrative nucleoside transporter 1 testing in pancreatic ductal adenocarcinoma: a comparison between murine and rabbit antibodies , 2015, Histopathology.
[4] Karin Haustermans,et al. Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials). , 2014, European journal of cancer.
[5] B. Dörken,et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] V. Heinemann,et al. Human equilibrative nucleoside transporter 1 is not predictive for gemcitabine efficacy in advanced pancreatic cancer: translational results from the AIO-PK0104 phase III study with the clone SP120 rabbit antibody. , 2014, European Journal of Cancer.
[7] David Cunningham,et al. O-0003NAPOLI-1: RANDOMIZED PHASE 3 STUDY OF MM-398 (NAL-IRI), WITH OR WITHOUT 5-FLUOROURACIL AND LEUCOVORIN, VERSUS 5-FLUOROURACIL AND LEUCOVORIN, IN METASTATIC PANCREATIC CANCER PROGRESSED ON OR FOLLOWING GEMCITABINE-BASED THERAPY , 2014 .
[8] P. Illei,et al. O-0004SPARC ANALYSIS IN THE PHASE III MPACT TRIAL OF NAB-PACLITAXEL (NAB-P) PLUS GEMCITABINE (GEM) VS GEM ALONE FOR PATIENTS WITH METASTATIC PANCREATIC CANCER (PC) , 2014 .
[9] B. Dörken,et al. Hent1 expression in patients with pancreatic cancer treated with gemcitabine after curative intended resection: Results from the CONKO-001 trial. , 2014 .
[10] K. Perez,et al. Nab-paclitaxel (nab-P) combined with FOLFOX for advanced pancreatic cancer: A phase I study. , 2014 .
[11] John R. Mackey,et al. Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. , 2014, Journal of the National Cancer Institute.
[12] V. Heinemann,et al. Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] D. Elashoff,et al. A Meta-Analysis of Gemcitabine Biomarkers in Patients With Pancreaticobiliary Cancers , 2013, Pancreas.
[14] David Goldstein,et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.
[15] Isabelle Salmon,et al. Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. , 2012, Gastroenterology.
[16] F. Fein,et al. FOLFIRI.3 (CPT-11 plus folinic acid plus 5-FU) alternating with gemcitabine or gemcitabine (G) alone in patients (pts) with previously untreated metastatic pancreatic adenocarcinoma (MPA): Results of the randomized multicenter AGEO phase II trial FIRGEM. , 2012 .
[17] A. Maitra,et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Pierre Michel,et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.
[19] C. Tudur-Smith,et al. Meta-analysis of immunohistochemical prognostic markers in resected pancreatic cancer , 2011, British Journal of Cancer.
[20] N. Jamieson,et al. Tissue Biomarkers for Prognosis in Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-analysis , 2011, Clinical Cancer Research.
[21] T. Conroy,et al. Capecitabine plus oxaliplatin (XELOX) versus 5‐fluorouracil/leucovorin plus oxaliplatin (FOLFOX‐6) as first‐line treatment for metastatic colorectal cancer , 2011, International journal of cancer.
[22] N. Kearney,et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. , 2011, European journal of cancer.
[23] B. Chauffert,et al. Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301) , 2010, Gut.
[24] H. Friess,et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. , 2010, JAMA.
[25] W. Scheithauer,et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] Adam P Dicker,et al. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. , 2009, Gastroenterology.
[27] Y. Bang,et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[28] W. Scheithauer,et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] R. Labianca,et al. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer , 2008, BMC Cancer.
[30] G. Chatellier,et al. Meta-Analysis of Randomised Trials Comparing Gemcitabine-Based Doublets versus Gemcitabine Alone in Patients with Advanced and Metastatic Pancreatic Cancer , 2007, Drugs & aging.
[31] C. Iacobuzio-Donahue,et al. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] J. Taïeb,et al. FOLFIRI.3, a new regimen combining 5-fluorouracil, folinic acid and irinotecan, for advanced pancreatic cancer: results of an Association des Gastro-Enterologues Oncologues (Gastroenterologist Oncologist Association) multicenter phase II study. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[33] C. Cass,et al. Distribution and Functional Characterization of Equilibrative Nucleoside Transporter-4, a Novel Cardiac Adenosine Transporter Activated at Acidic pH , 2006, Circulation research.
[34] Patrick Soon-Shiong,et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.
[35] R. Labianca,et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] C. Haglund,et al. Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry , 2005, Gut.
[37] G. Launoy,et al. Incidence of gastrointestinal cancers in France. , 2004, Gastroenterologie clinique et biologique.
[38] A. Matakidou,et al. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] M. Coleman,et al. EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[40] E. Van Cutsem,et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] E Harrison,et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] C. R. Crawford,et al. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. , 1998, Cancer research.
[43] D. V. Von Hoff,et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] P. Rougier,et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] L. Johnson,et al. Thymidylate synthase overproduction and gene amplification in fluorodeoxyuridine-resistant human cells. , 1985, Molecular pharmacology.